Skip to content

US · GTBP · BIOTECHNOLOGY

GT Biopharma, Inc. (GTBP) intrinsic value and stock valuation

$2.96as of 2026-11-21 · Mkt cap 10.02M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

GT Biopharma, Inc. DCF and intrinsic value

InvestorsCraft values GTBP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GTBP’s statements →

GT Biopharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Francisco, CA 94104 gtbiopharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-28.35M
20112025
Free cash flow
-$-12.91M
20112025
Total equity
$5.79M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-12.42M-$-14.36M-$-13.58M-$-21.26M-$-57.52M
Net income-$-28.35M-$-13.16M-$-7.6M-$-20.88M-$-58.01M
EPSd-$-5.15M-$-6.93M-$-5.63M-$-655.16K-$-2.06M
Operating cash flow-$-12.91M-$-12.9M-$-8.85M-$-15.22M-$-15.61M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-12.91M-$-12.9M-$-8.85M-$-15.22M-$-15.61M
Total assets$8.11M$4.23M$14.1M$16.7M$32.2M
Total debt$0.00$0.00$60K$170K$30K
Net debt-$-6.81M-$-3.95M-$-1.02M-$-5.5M-$-8.94M
Total equity$5.79M-$-1.67M$7.48M$11.7M$21.9M
Cash and short-term investments$6.81M$3.95M$14M$16.5M$32M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$3.47M$5.8M$6.47M$8.81M$9.59M
Selling, general and administrative expenses$8.95M$8.57M$7.11M$12.5M$47.9M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$12.4M$14.4M$13.6M$21.3M$57.5M
Cost and expenses$12.4M$14.4M$13.6M$21.3M$57.5M
Interest income$120K$400K$780K$290K$40K
Interest expense$130K$0.00$210K$10K$720K
Depreciation and amortization$0.00$0.00$13.6M$0.00$0.00
Ebitda-$-28.23M-$-13.16M$5.98M-$-20.96M-$-57.48M
Operating income-$-12.42M-$-14.36M-$-13.58M-$-21.26M-$-57.52M
Total other income/expenses, net-$-15.93M$1.2M$5.98M$370K-$-500K
Income before tax-$-28.35M-$-13.16M-$-7.6M-$-20.88M-$-58.01M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-28.35M-$-13.16M-$-7.6M-$-20.88M-$-58.01M
Weighted average shares outstanding$5.51M$1.9M$1.35M$31.9M$28.2M
Weighted average diluted shares outstanding$5.51M$1.9M$1.35M$31.9M$28.2M
Balance sheet
20252024202320222021
Cash and short-term investments$6.81M$3.95M$14M$16.5M$32M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.11M$4.23M$14.1M$16.6M$32.2M
Property, plant and equipment, net$0.00$0.00$50K$170K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$50K$170K$0.00
Total assets$8.11M$4.23M$14.1M$16.7M$32.2M
Accounts payable$750K$3.85M$4.33M$3.14M$8.19M
Short-term debt$0.00$0.00$60K$110K$30K
Deferred revenue$0.00$0.00$0.00$0.00$1.9M
Total current liabilities$2.32M$5.9M$6.63M$4.94M$10.3M
Long-term debt$0.00$0.00$0.00$60K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$60K$0.00
Capital lease obligations$0.00$0.00$60K$170K$0.00
Total liabilities$2.32M$5.9M$6.63M$5M$10.3M
Common stock$30K$0.00$0.00$30K$1.15M
Retained earnings-$-723.9M-$-695.23M-$-682.07M-$-674.47M-$-653.58M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$1.11M
Total equity$5.79M-$-1.67M$7.48M$11.7M$21.9M
Total investments$0.00$0.00$12.9M$10.8M$23M
Total debt$0.00$0.00$60K$170K$30K
Net debt-$-6.81M-$-3.95M-$-1.02M-$-5.5M-$-8.94M
Cash flow statement
20252024202320222021
Net income-$-28.35M-$-13.16M-$-7.6M-$-20.88M-$-58.01M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$430K$230K$2.2M$7.65M$33.9M
Change in working capital-$-920K$830K$1.82M-$-1.99M$7.94M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.3M$940K$1.96M-$-2.03M$7.08M
Net cash provided by operating activities-$-12.91M-$-12.9M-$-8.85M-$-15.22M-$-15.61M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$12.9M-$-2.01M$12.1M-$-23.04M
Common stock issued$16M$2.98M$6.27M$0.00$24.7M
Common stock repurchased$0.00$0.00$0.00-$-220K$0.00
Dividends paid-$-230K$0.00$0.00$0.00$0.00
Net cash used for financing activities$15.8M$2.98M$6.27M-$-220K$42.3M
Net change in cash$2.86M$2.96M-$-4.59M-$-3.3M$3.67M
Cash at end of period$6.91M$4.04M$1.08M$5.67M$8.97M
Operating cash flow-$-12.91M-$-12.9M-$-8.85M-$-15.22M-$-15.61M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-12.91M-$-12.9M-$-8.85M-$-15.22M-$-15.61M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About GT Biopharma, Inc.

        GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.

        CEO
        Michael Martin Breen
        Employees
        1
        Beta
        0.84

        Explore

        Frequently asked questions

        What is the intrinsic value of GT Biopharma, Inc. (GTBP)?

        InvestorsCraft does not currently publish an intrinsic value for GTBP. How the IC value is calculated.

        Is GTBP undervalued?

        InvestorsCraft does not publish an undervaluation signal for GTBP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.